Results 191 to 200 of about 1,913,070 (304)

Refractory chronic lymphocytic leukemia-associated pruritus successfully treated with nemolizumab. [PDF]

JAAD Case Rep
Sellars IA, Jani Y, Cohen DJ.
europepmc   +1 more source

Albumin activates the AKT signalling pathway and protects B-chronics lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis [PDF]

, 2002
Palmqvist, L, Jones, DT, Ganeshaguru, K, Prentice, HG, Mehta, AB, Anderson, RJ, Bruckdorfer, KR, Jackson, TR, Low, SY, Wickremasinghe, RG, Hoffbrand, AV   +10 more
core  

Functional assessment of inherited myeloid neoplasm‐associated SAMD9L germline variants via Monoallelic CRISPR modelling

British Journal of Haematology, EarlyView.
Summary While the majority of myeloid neoplasms are sporadic, the increasing application of germline genetic testing has led the World Health Organization to designate ‘Myeloid malignancies with germline predisposition’ as a distinct clinical entity, carrying major implications for clinical care and research.
Elena Vuelta, Alessandro Liquori, Matias Morín, Lucia Soletto, Miguel Ángel Marugal, Marta Santiago‐Balsera, Miguel Gallardo, Miguel Ángel Moreno‐Pelayo, José Cervera, Alejandra Sanjuan‐Pla   +9 more
wiley   +1 more source

Prolymphocytic Progression in Chronic Lymphocytic Leukemia Without Richter Transformation: An Eighteen-Year Clinical-Diagnostic Correlation. [PDF]

Case Rep Hematol
Ravisankar HV, Umrau K, Cheng L, Czader M, Gulati R.   +4 more
europepmc   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Postoperative Complications Following Total Knee Arthroplasty in Patients with Chronic Lymphocytic Leukemia. [PDF]

J Clin Med
Wood B, Tummala S, Thota DR, Sambandam S.   +3 more
europepmc   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma

British Journal of Haematology, EarlyView.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan, Ran Liu, Hsin‐Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani   +8 more
wiley   +1 more source

Lymphocyte count and risk of chronic lymphocytic leukemia. [PDF]

J Natl Cancer Inst
Pahnke S, Alcala K, Bulos Salim C, Cortez Cardoso Penha R, Park HA, Mckay J, Johansson M.   +6 more
europepmc   +1 more source

Editorial: Reviews in hematologic malignancies: 2023

Frontiers in Oncology
Billy Michael Chelliah Jebaraj, Michael Liew, Felix Seyfried   +2 more
doaj   +1 more source